MCRB (Seres Therapeutics) Marketable Securities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MCRB Seres Therapeutics Inc MCRB
13 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Marketable Securities?

Seres Therapeutics MCRB -4.80% 13 Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus rates MCRB with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Seres Therapeutics's Marketable Securities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Seres Therapeutics  (NAS:MCRB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Seres Therapeutics Marketable Securities Related Terms

Seres Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics Marketable Securities Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 110.70 18.31 0.00 0.00 0.00

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MCRB
13GF Score
Seres Therapeutics Inc MCRB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Seres Therapeutics (MCRB) has a Marketable Securities of $0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Seres Therapeutics and its competitors.
Is Seres Therapeutics' Marketable Securities too high?
Seres Therapeutics' current Marketable Securities is $0.00 Mil. Overall, Seres Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' Marketable Securities compare to IBO and TIL?
Seres Therapeutics' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (MCRB) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Seres Therapeutics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Seres Therapeutics (MCRB), the current Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges 1S90:Germany
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
13GF Score

Get the complete analysis for MCRB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price